These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 31151624)
41. Alkyl glucopyranoside-based niosomes containing methotrexate for pharmaceutical applications: evaluation of physico-chemical and biological properties. Muzzalupo R; Tavano L; La Mesa C Int J Pharm; 2013 Dec; 458(1):224-9. PubMed ID: 24060370 [TBL] [Abstract][Full Text] [Related]
42. Synthesis of multifunctional Fe You L; Liu X; Fang Z; Xu Q; Zhang Q Mater Sci Eng C Mater Biol Appl; 2019 Jan; 94():291-302. PubMed ID: 30423711 [TBL] [Abstract][Full Text] [Related]
43. Stability, biocompatibility and antioxidant activity of PEG-modified liposomes containing resveratrol. Caddeo C; Pucci L; Gabriele M; Carbone C; Fernàndez-Busquets X; Valenti D; Pons R; Vassallo A; Fadda AM; Manconi M Int J Pharm; 2018 Mar; 538(1-2):40-47. PubMed ID: 29294324 [TBL] [Abstract][Full Text] [Related]
44. Liposome and niosome preparation using a membrane contactor for scale-up. Pham TT; Jaafar-Maalej C; Charcosset C; Fessi H Colloids Surf B Biointerfaces; 2012 Jun; 94():15-21. PubMed ID: 22326648 [TBL] [Abstract][Full Text] [Related]
45. Dermal delivery of selected hydrophilic drugs from elastic liposomes: effect of phospholipid formulation and surfactants. Ita KB; Du Preez J; Lane ME; Hadgraft J; du Plessis J J Pharm Pharmacol; 2007 Sep; 59(9):1215-22. PubMed ID: 17883892 [TBL] [Abstract][Full Text] [Related]
46. Structural evaluation of phospholipidic nanovesicles containing small amounts of chitosan. Mertins O; Cardoso MB; Pohlmann AR; da Silveira NP J Nanosci Nanotechnol; 2006 Aug; 6(8):2425-31. PubMed ID: 17037851 [TBL] [Abstract][Full Text] [Related]
47. Optimization of the process variables of tilianin-loaded composite phospholipid liposomes based on response surface-central composite design and pharmacokinetic study. Zeng C; Jiang W; Tan M; Yang X; He C; Huang W; Xing J Eur J Pharm Sci; 2016 Mar; 85():123-31. PubMed ID: 26883760 [TBL] [Abstract][Full Text] [Related]
48. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Abdelkader H; Alani AW; Alany RG Drug Deliv; 2014 Mar; 21(2):87-100. PubMed ID: 24156390 [TBL] [Abstract][Full Text] [Related]
49. Effect of chemical composition and sonication procedure on properties of food-grade soy lecithin liposomes with added glycerol. Taladrid D; Marín D; Alemán A; Álvarez-Acero I; Montero P; Gómez-Guillén MC Food Res Int; 2017 Oct; 100(Pt 1):541-550. PubMed ID: 28873719 [TBL] [Abstract][Full Text] [Related]
50. Design and characterization of ofloxacin niosomes. Ramalingam N; Natesan G; Dhandayuthapani B; Perumal P; Balasundaram J; Natesan S Pak J Pharm Sci; 2013 Nov; 26(6):1089-96. PubMed ID: 24191311 [TBL] [Abstract][Full Text] [Related]
51. Non-ionic surfactant vesicles mediated transcutaneous immunization against hepatitis B. Maheshwari C; Pandey RS; Chaurasiya A; Kumar A; Selvam DT; Prasad GB; Dixit VK Int Immunopharmacol; 2011 Oct; 11(10):1516-22. PubMed ID: 21609785 [TBL] [Abstract][Full Text] [Related]
52. Sorbitan ester niosomes for topical delivery of rofecoxib. Das MK; Palei NN Indian J Exp Biol; 2011 Jun; 49(6):438-45. PubMed ID: 21702223 [TBL] [Abstract][Full Text] [Related]
53. Design and in vitro characterization of small unilamellar niosomes as ophthalmic carrier of dorzolamide hydrochloride. Hasan AA Pharm Dev Technol; 2014 Sep; 19(6):748-54. PubMed ID: 23964893 [TBL] [Abstract][Full Text] [Related]
54. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization. Abdelkader H; Ismail S; Kamal A; Alany RG Pharmazie; 2010 Nov; 65(11):811-7. PubMed ID: 21155387 [TBL] [Abstract][Full Text] [Related]
55. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. El-Ridy MS; Abdelbary A; Essam T; El-Salam RM; Kassem AA Drug Dev Ind Pharm; 2011 Dec; 37(12):1491-508. PubMed ID: 21707323 [TBL] [Abstract][Full Text] [Related]
56. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. Gupta M; Goyal AK; Paliwal SR; Paliwal R; Mishra N; Vaidya B; Dube D; Jain SK; Vyas SP J Liposome Res; 2010 Dec; 20(4):341-50. PubMed ID: 20163329 [TBL] [Abstract][Full Text] [Related]
57. Glycoside-based niosomal nanocarrier for enhanced in-vivo performance of Cefixime. Imran M; Shah MR; Ullah F; Ullah S; Elhissi AM; Nawaz W; Ahmad F; Sadiq A; Ali I Int J Pharm; 2016 May; 505(1-2):122-32. PubMed ID: 27050867 [TBL] [Abstract][Full Text] [Related]
58. Niosomes as Nano-Delivery Systems in the Pharmaceutical Field. Cerqueira-Coutinho C; Dos Santos EP; Mansur CR Crit Rev Ther Drug Carrier Syst; 2016; 33(2):195-212. PubMed ID: 27651102 [TBL] [Abstract][Full Text] [Related]
59. A new approach for the evaluation of niosomes as effective transdermal drug delivery systems. Muzzalupo R; Tavano L; Cassano R; Trombino S; Ferrarelli T; Picci N Eur J Pharm Biopharm; 2011 Sep; 79(1):28-35. PubMed ID: 21303691 [TBL] [Abstract][Full Text] [Related]
60. New liposomal doxorubicin nanoformulation for osteosarcoma: Drug release kinetic study based on thermo and pH sensitivity. Haghiralsadat F; Amoabediny G; Sheikhha MH; Zandieh-Doulabi B; Naderinezhad S; Helder MN; Forouzanfar T Chem Biol Drug Des; 2017 Sep; 90(3):368-379. PubMed ID: 28120466 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]